☆ 4.6 Article

Enhancement of SARS-CoV-2 N Antigen-Specific T Cell Functionality by Modulating the Autophagy-Mediated Signal Pathway in Mice

VIRUSES-BASEL (2023)

Related references

Note: Only part of the references are listed.

Article Immunology

Heterologous chimpanzee adenovirus vector immunizations for SARS- CoV-2 spike and nucleocapsid protect hamsters against COVID-19

Mohadeseh Hasanpourghadi et al.

Summary: COVID-19 vaccines have a limited duration of protection due to viral variants. In this study, hamsters were vaccinated with two adenovirus vectors expressing S and N proteins of SARS-CoV-2. The S protein vaccine provided protection and accelerated recovery upon SARS-CoV-2 challenge, while the combination of S and N protein vaccines enhanced the protection. The results suggest that incorporating the less variable N protein in the current S protein-based vaccines can potentiate and prolong the immune response.

MICROBES AND INFECTION (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19

Luigi Aurisicchio et al.

Summary: COVID-eVax, a DNA vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, was well tolerated and induced an immune response in up to 90% of volunteers, but did not induce neutralizing antibodies. The T cell-mediated immune response is significant and should be further studied for its protective capacity.

MOLECULAR THERAPY (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine

Ziyu Wen et al.

Summary: The immune escape mutations of SARS-CoV-2 variants pose a challenge to current vaccines. Developing novel SARS-CoV-2 vaccines is important for future epidemic prevention. This study successfully constructed a Mycobacterium smegmatis bacterial surface display system to carry S and N antigens of SARS-CoV-2, which effectively elicited T cell immune responses and showed potential cross-reactivity.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

Alison Tarke et al.

Summary: T cell responses induced by different vaccine platforms cross-recognize early SARS-CoV-2 variants, while memory B cells and neutralizing antibodies show significant decreases. The majority of memory T cell responses are preserved against variants, with lower recognition of Omicron by memory B cells.

CELL (2022)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex

Dhiraj Mannar et al.

Summary: The newly reported Omicron variant shows new salt bridges and hydrogen bonds formed by mutated residues in the receptor binding domain, compensating for reduced ACE2 binding affinity. It also exhibits increased antibody evasion, which likely contributes to its rapid spread.

SCIENCE (2022)

Add to Collection

Article Immunology

Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State

Abbye E. McEwen et al.

Summary: Among 20 vaccine breakthrough cases at the institution, all infections were caused by variants of concern, with a median Ct value of 20.2. Variants of concern were significantly more prevalent in breakthrough infections compared to contemporaneous samples sequenced in the laboratory.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Roanne Keeton et al.

Summary: Despite reduced neutralizing antibody activity, T cell responses induced by vaccination or infection can cross-recognize the Omicron variant and provide protection.

NATURE (2022)

Add to Collection

Article Immunology

Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro

Ning Luan et al.

Summary: This study examined the risk of antibody-dependent enhancement (ADE) of infection with immune sera from mice and humans vaccinated with alum-adjuvanted inactivated SARS-CoV-2 vaccines. The results showed that the vaccines did not enhance SARS-CoV-2 infection in vitro, suggesting that the lower protection rate may be due to lower neutralizing antibody titers or pulmonary eosinophilic immunopathology. Adjusting the immunization schedule and adjuvants may improve the efficacy of inactivated and spike protein-based subunit SARS-CoV-2 vaccines.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Cellular Immunity-The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination

Dragan Primorac et al.

Summary: This study suggests that individuals who have recovered from SARS-CoV-2 and have been vaccinated have higher levels of cellular immunity and antibody titers, providing long-term protection. Moreover, antibody levels show a negative correlation with the time since the last contact with the viral antigen.

VACCINES (2022)

Add to Collection

Article Medicine, General & Internal

Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals

Lorenzo De Marco et al.

Summary: This cohort study in Italy showed that the SARS-CoV-2 Omicron variant was recognized by the cellular component of the immune system in immunized adults, despite mutations in the spike protein. It is reasonable to assume that protection from hospitalization and severe disease will be maintained.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Pharmacology & Pharmacy

Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants

Minchao Li et al.

Summary: The emergence of SARS-CoV-2 variants has reduced the effectiveness of existing vaccines and antibody therapy against COVID-19. However, the use of soluble human ACE2 (shACE2) or dog ACE2 (dACE2(24-83)) as decoys can effectively block the infections of SARS-CoV-2 variants. This study highlights a promising therapeutic strategy.

ANTIVIRAL RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Looking beyond COVID-19 vaccine phase 3 trials

Jerome H. Kim et al.

Summary: Following the announcement of COVID-19 vaccine efficacy in clinical trials, a comprehensive strategy is needed for global vaccination, including manufacturing, support, supply coordination, equitable distribution, and logistics. Additionally, addressing scientific questions to improve vaccine efficacy is crucial for ending the pandemic effectively and efficiently.

NATURE MEDICINE (2021)

Add to Collection

Article Virology

Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes

Minchao Li et al.

Summary: Developing a global HCoVs vaccine is crucial in the field of public health with the rapid spread of COVID-19. The novel antigen design with broad coverage has the potential to induce strong CTL responses.

VIRUSES-BASEL (2021)

Add to Collection

Article Immunology

The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients

Huanle Luo et al.

Summary: Increasing evidence suggests immune responses are associated with COVID-19 outcomes. IgG subclasses and cytokines had significant correlations with disease severity. Older patients and those with comorbidities showed higher antibody levels and affected IgG1 and IgG3 responses.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Infectious Diseases

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay

Irene Cassaniti et al.

Summary: The study evaluated the SARS-CoV-2 T-cell response in COVID-19 convalescent patients and unexposed individuals, showing that a majority of convalescent patients had a positive response to at least one SARS-CoV-2 antigen, which could last up to 12 months. The findings suggest that the SARS-CoV-2 T-cell response is primarily mediated by CD4 T cells.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Medicine, General & Internal

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Ezgi Hacisuleyman et al.

Summary: Despite evidence of vaccine efficacy, two fully vaccinated individuals developed mild symptoms of Covid-19 and were infected with variants of SARS-CoV-2. Sequencing of the virus isolates revealed novel mutations, highlighting the potential risk of illness post-vaccination and subsequent infection with variant virus. Efforts to prevent, diagnose, and characterize variants in vaccinated individuals are crucial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Immunology

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

Ian McDonald et al.

Summary: This study provides a comparative evaluation of different vaccine platforms in terms of immunogenicity and efficacy. Vaccines generally result in mild and self-limiting adverse events. Different vaccines show varying levels of immunogenicity and efficacy.

NPJ VACCINES (2021)

Add to Collection

Review Virology

The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation

Zhihua Bai et al.

Summary: The N protein of SARS-CoV-2 shares high homology with other coronavirus N proteins, indicating its potential significance as a drug target or vaccine candidate. Further research is needed to explore the functional aspects of this protein in controlling the spread of the virus.

VIRUSES-BASEL (2021)

Add to Collection

Article Immunology

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Bo Diao et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Nina Le Bert et al.

NATURE (2020)

Add to Collection

Article Immunology

Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Yanchun Peng et al.

NATURE IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets

Sergio C. Oliveira et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Nisreen M. A. Okba et al.

EMERGING INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, Research & Experimental

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Li Liu et al.

JCI INSIGHT (2019)

Add to Collection

Review Microbiology

Autophagy during viral infection - a double-edged sword

Younho Choi et al.

NATURE REVIEWS MICROBIOLOGY (2018)

Add to Collection

Article Cell Biology

Autophagy and proteasome interconnect to coordinate cross-presentation through MHC class I pathway in B cells

Vijayendra Dasari et al.

IMMUNOLOGY AND CELL BIOLOGY (2016)

Add to Collection

Article Chemistry, Medicinal

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

Qidi Wang et al.

ACS INFECTIOUS DISEASES (2016)

Add to Collection

Review Immunology

Autophagy and autophagy-related proteins in the immune system

Shusaku T. Shibutani et al.

NATURE IMMUNOLOGY (2015)

Add to Collection

Article Multidisciplinary Sciences

Regulation of SIV Antigen-Specific CD4+T Cellular Immunity via Autophagosome-Mediated MHC II Molecule-Targeting Antigen Presentation in Mice

Yi Jin et al.

PLOS ONE (2014)

Add to Collection

Article Virology

Circumventing Antivector Immunity by Using Adenovirus-Infected Blood Cells for Repeated Application of Adenovirus-Vectored Vaccines: Proof of Concept in Rhesus Macaques

Caijun Sun et al.

JOURNAL OF VIROLOGY (2012)

Add to Collection

Article Immunology

Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells

Jamie M. Ireland et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2011)

Add to Collection

Article Biochemistry & Molecular Biology

Methods in Mammalian Autophagy Research

Noboru Mizushima et al.

CELL (2010)

Add to Collection

Article Infectious Diseases

Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeys

Caijun Sun et al.

JOURNAL OF INFECTION (2010)

Add to Collection

Review Microbiology

The spike protein of SARS-CoV - a target for vaccine and therapeutic development

Lanying Du et al.

NATURE REVIEWS MICROBIOLOGY (2009)

Add to Collection

Article Immunology

Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes

Dorothee Schmid et al.

IMMUNITY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.